Wednesday, April 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Commodities

Paramount Gold Nevada Nears Crucial State-Level Approvals for Grassy Mountain

SiterGedge by SiterGedge
February 20, 2026
in Commodities, Gold & Precious Metals, Penny Stocks
0
Paramount Gold Nevada Stock
0
SHARES
24
VIEWS
Share on FacebookShare on Twitter

Following a pivotal federal regulatory clearance secured in late January, Paramount Gold Nevada is now advancing toward the final administrative hurdles required to commence construction at its Grassy Mountain gold project. Investor attention is currently fixed on the permitting timeline within the state of Oregon, with a key question emerging: can the company secure the necessary green light to begin building within the first half of 2026?

The company’s recent milestone was the receipt of the Federal Record of Decision (ROD) on January 29, formally concluding the National Environmental Policy Act (NEPA) review process at the federal level. Paramount Gold Nevada, carrying a market valuation of approximately $184 million, has seen its shares trade around $2.19, a price that reflects market anticipation surrounding the remaining state-level authorizations.

Sector Activity and Project Timeline

The broader mining landscape in the Western United States is currently dynamic. Recent days have seen several industry peers announce significant developments. i-80 Gold reported annual revenue of $95.2 million and outlined plans for a recapitalization by the end of March. Meanwhile, Kinross Gold posted a substantial net profit of $2.39 billion, a result buoyed by high realized gold prices.

Furthermore, sustained merger and acquisition interest in Nevada is highlighted by the recent acquisition of the South Cortez and South Tonkin projects by a subsidiary of Palisades Goldcorp. For Paramount Gold Nevada, the critical path forward involves converting its federal success into final state permits from the Oregon Department of Geology and Mineral Industries (DOGAMI).

Should investors sell immediately? Or is it worth buying Paramount Gold Nevada?

The current schedule points toward the final state permits being secured by the end of the first or early in the second quarter of 2026. An initial draft of the consolidated permit package was already submitted in December.

Upcoming Catalysts and Shareholder Base

In parallel with the permitting work, the engineering firm Ausenco is preparing an updated feasibility study. This revised analysis, expected for release in the first half of 2026, will provide fresh economic data on the Grassy Mountain project’s viability.

The shareholder structure during this transitional phase demonstrates notable concentration. Major investor Fangjian Yuan, for instance, maintains a significant stake of 8.47%, equivalent to 6.72 million shares, signaling continued commitment from key backers.

With the permitting process anticipated to conclude by the end of the second quarter of 2026 and the updated feasibility study due for publication, Paramount Gold Nevada is approaching the definitive milestones that will determine the future of its Grassy Mountain development.

Ad

Paramount Gold Nevada Stock: Buy or Sell?! New Paramount Gold Nevada Analysis from April 8 delivers the answer:

The latest Paramount Gold Nevada figures speak for themselves: Urgent action needed for Paramount Gold Nevada investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 8.

Paramount Gold Nevada: Buy or sell? Read more here...

Tags: Paramount Gold Nevada
SiterGedge

SiterGedge

Related Posts

Plug Power Stock
Analysis

Hydrogen’s Divergent Paths: From Record Backlogs to Research Labs in April 2026

April 8, 2026
Uranium Energy Stock
Analysis

Uranium Energy Shares Face Dilution Concerns Amid Expansion Plans

April 8, 2026
Battalion Oil Stock
Analysis

Battalion Oil Shares Surge on Operational Milestones and Strategic Moves

April 8, 2026
Next Post
Rocket Lab USA Stock

Rocket Lab Shares Gain Momentum Amid Sector Strength and Operational Milestones

Salesforce Stock

Salesforce's Acquisition Spree Defies a Slumping Software Sector

Genuine Parts Stock

Genuine Parts Charts Independent Future with Planned Corporate Split

Recommended

Coeur Mining Stock

Coeur Mining Faces Market Scrutiny Following Major Acquisition

2 weeks ago
Geron Stock

Geron Shares Plunge Following Disappointing Quarterly Results

5 months ago
Lynas Stock

A Compelling Case for Lynas as a Rare Earths Powerhouse

5 months ago
Nuscale Power Stock

NuScale Power Shares Plunge Amid Growing Market Concerns

6 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Micron Navigates a Week of Competitive and Geopolitical Crosscurrents

Palantir’s Valuation Challenge: Strong Performance Meets Investor Skepticism

Microsoft’s AI Pivot: Broadening Copilot’s Horizon to Drive Growth

Hydrogen’s Divergent Paths: From Record Backlogs to Research Labs in April 2026

Amazon’s Dual Strategy: Shifting Costs While Investing in Logistics

Alphabet’s Strategic Push: Securing AI Dominance Through Partnerships and Investment

Trending

MSCI World ETF Stock
ETF

A Confluence of Catalysts: The iShares MSCI World ETF Faces a Transformative Season

by Rodolfo Hanigan
April 8, 2026
0

The iShares MSCI World ETF, the globe's largest equity exchange-traded fund, is navigating a period of significant...

D-Wave Quantum Stock

Mizuho Trims Price Target for D-Wave Quantum While Affirming Bullish Stance

April 8, 2026
BioNTech Stock

BioNTech Faces Mounting Analyst Skepticism Over Key Drug Trial

April 8, 2026
Micron Stock

Micron Navigates a Week of Competitive and Geopolitical Crosscurrents

April 8, 2026
Palantir Stock

Palantir’s Valuation Challenge: Strong Performance Meets Investor Skepticism

April 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • A Confluence of Catalysts: The iShares MSCI World ETF Faces a Transformative Season
  • Mizuho Trims Price Target for D-Wave Quantum While Affirming Bullish Stance
  • BioNTech Faces Mounting Analyst Skepticism Over Key Drug Trial

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com